GNE-781 (GNE781) is a novel, highly potent and selective inhibitor of CBP (Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein) with immunomodulatory and anticancer effects.

Inobrodib (CCS1477; BP-IN-1; CCS-1477) is a novel, potent and selective p300/CBP bromodomain inhibitor with anticancer activity.

IACS-9571 is a novel, potent and selective TRIM24 and BRPF1 inhibitor with IC50 value of 8 nM for TRIM24, and Kds of 31 nM and 14 nM for TRIM24 and BRPF1, respectively.

BAY-1238097 (the S-isomer of BAY-1238097) is a novel, potent and selective inhibitor of BET (bromodomain and extra-terminal) binding to histones and targeting the NFKB/TLR/JAK/STAT signalling pathways, MYC and E2F1-regulated genes, cell cycle regulation and chromatin structure.

BRM/BRG1 ATP Inhibitor-1 is an orally bioactive inhibitor of Brahma Homolog (BRM)/SMARCA2 ATPase with anticancer activity and has potential to be used for the treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers.

ABBV-744 (ABBV744) is a novel, potent and highly BDII-selective BET bromodomain inhibitor with anticancer and anti-inflammatory activity.

Molibresib (also known as GSK525762A, I-BET-762, GSK-525762) is a novel and potent inhibitor for BET (Bromodomain and Extra-Terminal) family of proteins with potential anti-inflammatory and anticancer activity.

GNE-272 is a novel, potent and selective in vivo chemical probe for and inhibitor of the CBP/EP300 bromodomains with IC50 values of 0.02, 0.03 and 13 μM for CBP, EP300 and BRD4, respectively.

ZL0420 (ZL-0420), an analog of ZL0454, is a novel potent and highly selective inhibitor of BRD4 (Bromodomain-Containing Protein 4) with anti-inflammatory activity.

BI-894999 is a novel, and selective BET inhibitor that has the potential to be used for the treatment of hematological malignancies by repression of super-enhancer driven oncogenes.